Tehila Ben-moshe

Title: Tehila Ben-Moshe: Innovator in Cancer Treatment

Introduction

Tehila Ben-Moshe is a prominent inventor based in Tel Aviv, Israel. She has made significant contributions to the field of cancer treatment through her innovative research and development of monoclonal antibodies. With a total of 3 patents to her name, her work is paving the way for new therapeutic approaches in oncology.

Latest Patents

Tehila's latest patents include groundbreaking methods of use for anti-ILT2 antibodies. This invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, along with pharmaceutical compositions and methods for producing them. Additionally, her patents outline methods for treating cancer that involve administering these antibodies or compositions. Another notable patent focuses on methods for decreasing soluble immune receptor CD28, which aims to improve cancer treatments and immunotherapies by reducing soluble immune receptor levels.

Career Highlights

Tehila Ben-Moshe is currently associated with Biond Biologics Ltd., where she continues to advance her research in immunotherapy and cancer treatment. Her innovative approaches have garnered attention in the scientific community, contributing to the development of effective cancer therapies.

Collaborations

Tehila collaborates with talented professionals in her field, including Ilana Mandel and Dana Haves Ziv. Their combined expertise enhances the research and development efforts at Biond Biologics Ltd.

Conclusion

Tehila Ben-Moshe's contributions to cancer treatment through her innovative patents and collaborations highlight her role as a leading inventor in the field. Her work continues to inspire advancements in medical science and offers hope for improved cancer therapies.